Arteris, INC Form 4 insider transactions

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 438 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold 258 shares of common stock to cover tax obligations from restricted stock unit release.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 50,000 common shares through a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana sold 6,909 shares of common stock for approximately $14.14 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris Director Saiyed Atiq Raza reported the sale of 63,118 common shares on August 5, 2025, executed under a pre-arranged 10b5-1 trading plan.

Arteris' Chief Operating Officer, Laurent R. Moll, sold 34,400 shares of common stock for approximately $13.57 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s CFO, Nicholas B. Hawkins, sold 11,276 shares of common stock for approximately $13.15 per share under a pre-arranged 10b5-1 trading plan.

Arteris Inc.'s President and CEO, Charles Janac, sold 144,245 shares of common stock for approximately $1.9 million under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s CFO, Nicholas B. Hawkins, sold 5,638 shares of common stock for a weighted average price of $9.0328 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris Director Saiyed Atiq Raza sold 29,544 shares of common stock for approximately $10.07 per share through a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,638 shares of common stock for approximately $10.50 per share under a Rule 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, has filed a Form 4 disclosing a planned sale of 736 common shares on July 29, 2025, under a pre-established 10b5-1 trading plan.

Arteris, Inc. Director and 10% Owner Saiyed Atiq Raza sold 1,136 shares of common stock at $10 per share on July 18, 2025, pursuant to a Rule 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel acquired 1,727 shares of common stock as fully vested restricted stock, representing deferred retainer fees.

Arteris, Inc. President and CEO Charles K. Janac reported the sale of 18,968 shares of common stock in early July, primarily to cover tax liabilities and under a pre-arranged trading plan.

Paul L. Alpern, VP and General Counsel of Arteris, Inc., reported the sale of 6,488 shares of common stock in early July 2025, primarily to cover tax liabilities from restricted stock unit releases and pursuant to a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, reported the sale of 6,258 shares of common stock in early July 2025, primarily to cover tax liabilities from restricted stock unit releases and through a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, reported the sale of 8,837 shares of common stock in early July 2025, primarily to cover tax obligations from restricted stock units and through a pre-established 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 294 shares of common stock on July 1, 2025, through a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza has filed a Form 4 indicating a pre-planned sale of 19,809 shares of common stock on June 27, 2025, at a weighted average price of $10.0203 per share, executed under a Rule 10b5-1 trading plan.

Arteris, Inc. President and CEO, Charles Janac, reported the sale of 21,286 shares of common stock in two separate transactions in late June and early July 2025, executed under pre-established 10b5-1 trading plans.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 11,276 shares of common stock in two transactions in late June and early July 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 11,276 shares of common stock over two days in June 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza reported a transfer of 19,287 shares of common stock from direct ownership to a revocable family trust, maintaining his overall beneficial interest.

Nicholas B. Hawkins, VP and Chief Financial Officer of Arteris, Inc., reported the sale of 3,770 shares of common stock on June 9, 2025, as part of a pre-scheduled 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana disclosed the sale of 19,287 shares of common stock and the transfer of 21,327 shares to a family trust.

Paul L. Alpern, VP and General Counsel of Arteris, Inc., sold 423 shares of common stock for a weighted average price of $7.6618 per share, as part of a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Charles Janac, reported the sale of 2,057 shares of common stock on June 4, 2025, as part of a pre-established 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold a total of 2,451 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 202 shares of common stock for $7.96 per share on June 4, 2025, as part of a pre-arranged 10b5-1 trading plan.